Screener
Innoviva, Inc. INVA ZEVTERA — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:26 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335235
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| GIAPREZA® | $22,299 | $17,329 | $42,530 | $35,602 |
| XACDURO® | 22,382 | 10,731 | 40,456 | 18,514 |
| XERAVA® | 6,739 | 7,094 | 9,367 | 11,317 |
| ZEVTERA® | 351 | 339 | 789 | 339 |
| Total net product sales | $51,771 | $35,493 | $93,142 | $65,772 |
Item 1. Financial Statements
FAQ
- What is Innoviva, Inc.'s ZEVTERA — revenue?
- Innoviva, Inc. (INVA) reported ZEVTERA — revenue of $351K in Q2 2026.
- How has Innoviva, Inc.'s ZEVTERA — revenue changed year-over-year?
- Innoviva, Inc.'s ZEVTERA — revenue increased by 3.5% year-over-year, from $339K to $351K.
- What does ZEVTERA — revenue mean?
- This metric represents the gross revenue generated from the sale or licensing of the ZEVTERA product line, excluding any pass-through taxes collected from customers. It serves as a key indicator of the commercial adoption and market penetration of this specific therapeutic asset within the company's infectious disease portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and financial contribution of this critical care asset independently of the company's broader royalty-based income.
Ask your AI about Innoviva, Inc.'s zevtera — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude